 Acromegaly and gastroenteropancreatic neuroendocrine tumors GEP-NETs are rare diseases that require life-long chronic treatment. Monthly somatostatin analog SSA injections are the standard of care as first-line medical treatment. Debiopharm is developing Debio 4126, a novel 3-month extended-release octreotide formulation, to optimize acromegaly and GEP-NET patient care by reducing injection frequency, which translates into... The post DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPER... 